Literature DB >> 9934864

Enhancement of glutathione S-transferase placental-form positive liver cell foci development by microcystin-LR in aflatoxin B1-initiated rats.

M Sekijima1, T Tsutsumi, T Yoshida, T Harada, F Tashiro, G Chen, S Z Yu, Y Ueno.   

Abstract

The objective of this study was to elucidate whether microcystin-LR (MC-LR), a hepatotoxic blue-green algal toxin in drinking water, is carcinogenic or possesses the ability to modulate aflatoxin B1 (AFB1)-induced hepatocarcinogenicity. In a medium-term liver bioassay, male Fischer 344 rats were given a single i.p. injection of diethylnitrosamine (DEN, 200 mg/kg) followed by an i.p. injection of MC-LR for 6 weeks after 2 weeks of DEN treatment. To study the synergism between AFB1 and MC-LR, DEN-treated rats were given an i.p. injection of AFB1 (0.5 mg/kg) dissolved in dimethyl sulfoxide (DMSO) followed by MC-LR at 2 weeks after the treatment. In a separate experiment, the rats were first given AFB1 (0.5 mg/kg) and 2 weeks later an i.p. injection of 1 or 10 microg/kg of MC-LR twice a week for 6 weeks. Most rats were subjected to a two-thirds partial hepatectomy (PH) at week 3 and were killed under anesthesia at week 8. Liver sections were analyzed for glutathione S-transferase placental form (GST-P) expression, and subjected to histopathological examination for phenotypic alteration of hepatocellular foci. In rats that did not receive DEN, MC-LR did not cause a significant increase in the numbers of GST-P-positive foci, whereas AFB1 induced a slight increase in GST-P-positive foci development. In rats given DEN, MC-LR enhanced the expression of GST-P-positive foci, as did AFB1 but no synergism was observed. Histopathological analysis revealed that the area of eosinophilic foci, a biomarker for preneoplastic liver lesion, markedly increased because of MC-LR. In rats given AFB1 as an initiator, treatment with MC-LR resulted in a synergistic increase in the development of GST-P-positive foci. These results suggest that the hepatocarcinogenicities of MC-LR and AFB1 can be predicted in experimental animals with a medium-term bioassay. Furthermore, tumor promoting activity of MC-LR was demonstrated in rats treated with AFB1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9934864     DOI: 10.1093/carcin/20.1.161

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Effect of microcystin-LR on protein phosphatase 2A and its function in human amniotic epithelial cells.

Authors:  Jing Liang; Tan Li; Ya-Li Zhang; Zong-Lou Guo; Li-Hong Xu
Journal:  J Zhejiang Univ Sci B       Date:  2011-12       Impact factor: 3.066

2.  Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B1-induced hepatotumorigenesis in mice.

Authors:  Min Lian; Ying Liu; Shun-Zhang Yu; Geng-Sun Qian; Shu-Guang Wan; Kenneth-R Dixon
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

3.  MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period.

Authors:  Tarana Arman; J Allen Baron; Katherine D Lynch; Laura A White; Johnny Aldan; John D Clarke
Journal:  Toxicology       Date:  2021-11-02       Impact factor: 4.221

Review 4.  Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs.

Authors:  Ioannis Sainis; Demosthenes Fokas; Katerina Vareli; Andreas G Tzakos; Valentinos Kounnis; Evangelos Briasoulis
Journal:  Mar Drugs       Date:  2010-03-15       Impact factor: 5.118

5.  Impact of Microcystin-LR on Liver Function Varies by Dose and Sex in Mice.

Authors:  Igor Mrdjen; Mark A Morse; Randall J Ruch; Thomas J Knobloch; Shambhunath Choudhary; Christopher M Weghorst; Jiyoung Lee
Journal:  Toxins (Basel)       Date:  2018-10-28       Impact factor: 4.546

6.  Magnetic resonance imaging for rapid screening for the nephrotoxic and hepatotoxic effects of microcystins.

Authors:  Aleksandra Milutinović; Ruda Zorc-Pleskovič; Marko Živin; Andrej Vovk; Igor Serša; Dušan Šuput
Journal:  Mar Drugs       Date:  2013-08-05       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.